MS-Related Disorders ID’d by Proteomic Pattern Analysis Last Updated: September 19, 2011. CSF proteomic pattern analysis discriminates among multiple sclerosis-related disorde Proteomic pattern analysis of cerebrospinal fluid analysis using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry distinguishes between similar multiple sclerosis-related disorders, according to a study published online Sept.
For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone.
Interferon-b (IFN-b) is the major treatment for multiple sclerosis. However, this treatment is not always effective. Here we have found congruence in outcome between responses to IFN-b in experimental autoimmune encephalomyelitis (EAE) and relapsing-remitting multiple sclerosis (RRMS).
Interferon (IFN)-β is the treatment most often prescribed for relapsing–remitting multiple sclerosis (RRMS). 30–50% of MS patients, however, do not respond to IFN-β